2013 TAPTIMAT CT³N Award Recipients
The Center for Targeted Therapeutics and Translational Nanomedicine (CT³N) of the Institute for Translational Medicine and Therapeutics (ITMAT) announces its second round of successful applications for Pilot Grants.
The mission of these grants is to support early-stage experimental preclinical studies in targeted therapeutics and thus assist investigators in obtaining key data to seek extramural funding. CT³N is directed by Drs. Vladimir Muzykantov and Andrew Tsourkas.
The development of gold nanoclusters for sensitive CT cell trackingDavid Cormode, Radiology, Perelman School of Medicine
Victor Ferrari, Medicine-Cardiology, Perelman School of Medicine
- Directed Evolution of a Single Chain Antibody Fragment with High Affinity for Human and Rat ICAM-1
Colin Greineder, Emergency Medicine, Perelman School of Medicine
Casim Sarkar, Bioengineering, School of Engineering and Applied Sciences
- Tumor-targeted pH-responsive polymersomes
Zhiliang Cheng, Bioengineering, School of Engineering and Applied Sciences
- Design of yeast-secreted clickbodies directed against paired tumor antigens to target nanoparticles.
Natalie Scholler, Obstetrics and Gynecology, Perelman School of Medicine
- Predictive Computational Modeling Platform for Internalization of Functionalized Nanocarriers
Ravi Radhakrishnan, Biochemistry/Biophysics, Perelman School of Medicine
For more information, please visit the ITMAT website at www.itmat.upenn.edu.
Vladimir Muzykantov, MD, PhD, Director, PTT
Andrew Tsourkas, Ph.D., Associate Director, PTT
Garret A. FitzGerald, M.D., Director, ITMAT